NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $3.05 -0.03 (-0.97%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.00 -0.04 (-1.48%) As of 09/19/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Gossamer Bio Stock (NASDAQ:GOSS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$2.94▼$3.1850-Day Range$1.45▼$3.4652-Week Range$0.66▼$3.60Volume5.11 million shsAverage Volume4.59 million shsMarket Capitalization$693.51 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company Overview Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need. The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. In addition to these clinical-stage assets, Gossamer Bio maintains several earlier-stage programs targeting pathways such as integrin and TGF-β signaling. The company’s R&D efforts are supported by a combination of in-house research capabilities and external collaborations with academic centers and contract research organizations. Gossamer Bio completed its initial public offering in July 2019 and has since advanced multiple clinical trials across North America and selected international sites. The company is led by President and Chief Executive Officer Thomas A. Whiting, a veteran of the biopharmaceutical industry with over 25 years of drug development experience. Under his leadership, Gossamer Bio continues to build a multidisciplinary management team focused on accelerating the translation of scientific insights into therapeutic candidates.AI Generated. May Contain Errors. Read More Gossamer Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreGOSS MarketRank™: Gossamer Bio scored higher than 80% of companies evaluated by MarketBeat, and ranked 210th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Upside PotentialGossamer Bio has a consensus price target of $8.50, representing about 178.7% upside from its current price of $3.05.Amount of Analyst CoverageGossamer Bio has only been the subject of 3 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.28) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 23.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.39% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Gossamer Bio has recently increased by 7.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted10.39% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Gossamer Bio has recently increased by 7.56%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.66 News SentimentGossamer Bio has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Gossamer Bio this week, compared to 3 articles on an average week.Search Interest56 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 833% compared to the previous 30 days.MarketBeat Follows7 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GOSS Stock News HeadlinesGossamer Bio (GOSS): Assessing Valuation After Encouraging Phase 2 Data and Analyst OptimismSeptember 15, 2025 | finance.yahoo.comGossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 15, 2025 | americanbankingnews.comCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin.September 20 at 2:00 AM | Crypto 101 Media (Ad)Gossamer Bio (NASDAQ:GOSS) Raised to "Hold" at Wall Street ZenSeptember 15, 2025 | americanbankingnews.comGossamer Bio (GOSS) Is Up 17.7% After Seralutinib Gains Key FDA Support and Clinical ProgressSeptember 13, 2025 | finance.yahoo.comGossamer Bio's (GOSS) Overweight Rating Reiterated at Cantor FitzgeraldSeptember 13, 2025 | americanbankingnews.comPiper Sandler Reaffirms Their Buy Rating on Gossamer Bio (GOSS)September 12, 2025 | theglobeandmail.comH.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug ProspectsSeptember 12, 2025 | finance.yahoo.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $0.9046 at the start of the year. Since then, GOSS shares have increased by 237.2% and is now trading at $3.05. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) posted its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. The business earned $11.49 million during the quarter, compared to analysts' expectations of $4.12 million. Gossamer Bio had a negative trailing twelve-month return on equity of 1,774.72% and a negative net margin of 344.81%. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's top institutional investors include Acadian Asset Management LLC (3.14%), Geode Capital Management LLC (2.00%), Corient Private Wealth LLC (1.62%) and Monaco Asset Management SAM (1.56%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/05/2025Today9/20/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Price Target for Gossamer Bio$8.50 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+178.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.53 million Net Margins-344.81% Pretax Margin-353.62% Return on Equity-1,774.72% Return on Assets-46.73% Debt Debt-to-Equity Ratio6.70 Current Ratio4.40 Quick Ratio4.40 Sales & Book Value Annual Sales$114.70 million Price / Sales6.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book23.46Miscellaneous Outstanding Shares227,380,000Free Float212,146,000Market Cap$693.51 million OptionableOptionable Beta1.95 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:GOSS) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.